Keybanc maintains ICU Medical at Overweight, raises price target to $189 from $187
Keybanc maintained its Overweight rating on ICU Medical and increased its price target to $189 from $187, suggesting a 12.7% upside from the Nov 5 close of $167.65, according to the firm.
How this was made

The 30-second read
Why it matters
The upgrade may lead to incremental buying, but the magnitude is modest.
Market read
A small analyst rating change with limited immediate market impact.
What to watch
Potential upcoming earnings or product news could amplify the impact of the new target.
Background
Keybanc maintains an Overweight stance on ICU Medical and adjusts its price target upward.
Ticker impact
Keybanc raised ICU Medical's price target to $189 from $187, indicating a fresh analyst upgrade.
potential modest upside as investors price in the higher target
The new target suggests a 12.7% upside from the recent close, but no immediate catalyst beyond the rating change.
Market effects
Minor positive signal for the medical device sector as a leading analyst upgrades a peer.
Limited to U.S. equities; no broader regional effect.
Low global relevance.
Counterpoint
Investors may view the modest target raise as insufficient to justify a position given limited upside.
Key entities
- CompanyICU Medical
Medical device manufacturer listed on NYSE (ICU).
- Research FirmKeybanc
Equity research analyst firm issuing the rating.